About Our Grantmaking

LCFA grant awards help accelerate lung cancer research from bench to bedside with the goal of helping patients as soon as possible.

Why we award grants

We aim to attract the best and the brightest to lung cancer research. An LCFA grant award is typically $200,000 awarded to an early career researcher for work over two years. These significant awards allow researchers to set up and staff a lab and amass the crucial data needed to attract add-on funding for the project from major funding sources, such as the National Institutes of Health (NIH).

LCFA’s grant criteria is laser-pointed at research projects focused on improving the care and treatment of individuals with lung cancer. By funding their early research years, LCFA provides them the opportunity to stay focused on lung cancer throughout their careers.

Investing in Researchers

LCFA Early Career Researcher Grant Program

22 grants worth $4.4 Million

$43M in follow-on funding

10X Return On Investment in Early Career Researcher Grants

LCFA Young Investigator Grants

How your donation to LCFA funds lung cancer research

When you donate to LCFA, your donation is combined with donations from other donors and from our strategic partners. We use the combined funds to award significant lung cancer grants to researchers who present the “best in science” project.

Our grantmaking partners

LCFA pursues funding partnerships with industry and organizations like the International Association for the Study of Lung Cancer in an attempt to maximize the reach and productiveness of our lung cancer research grants.

We know the benefits of receiving this significant funding early-on. For example, researchers can amass data that attracts further funding for their projects from organizations like the National Institutes of Health.

Follow our Early Career Researchers

View all Researchers

  • Julie Wu, MD

    Staff Physician, Medical Oncology

    Precision oncology integrating evidence-based models into clinical practice to personalize treatment approaches

  • Jonathan Villena-Vargas, MD

    Thoracic Surgeon

    Characterizing T cell PD-1 response in the tumor-draining lymph nodes of early-stage NSCLC patients

  • Daniel J. Spakowicz, PhD

    Molecular Carcinogenesis and Chemoprevention

    The interplay between gut microbiome and immuno-oncology (IO) therapy responses for lung cancer